Stable Gastric PentadecapeptideBPC 157, Somatosensory Neurons and Their Protection and Therapeutic Extensions — A Survey

  title={Stable Gastric PentadecapeptideBPC 157, Somatosensory Neurons and Their Protection and Therapeutic Extensions — A Survey},
  author={Predrag Sikiric},


Peptidergic sensory neurons in the control of vascular functions: mechanisms and significance in the cutaneous and splanchnic vascular beds.
  • P. Holzer
  • Medicine
  • Reviews of physiology, biochemistry and pharmacology
  • 1992
Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons.
  • P. Holzer
  • Chemistry, Medicine
  • Pharmacological reviews
  • 1991
Traumatic brain injury in mice and pentadecapeptide BPC 157 effect
After an induced traumatic brain injury in mice by a falling weight, BPC 157 regimens demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24h post-injury period. Expand
Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity
Analysis of gastroprotective effect of the pentadecapeptide BPC 157 on gastric lesions produced in rats by 96% ethanol, restraint stress, and indomethacin provides evidence for complex synergistic interaction between the beneficial effectiveness of B PC 157 and peptidergic sensory afferent neuron activity. Expand
BPC 157 and blood vessels.
This review focuses on the described effects of BPC 157 on blood vessels after different types of damage, and elucidate by investigating different aspects of vascular response to injury (endotheliumExpand
Stable gastric pentadecapeptide BPC 157-NO-system relation.
Stable gastric pentadecapeptide BPC 157-NO-system-relation is reviewed, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury and how this advantage of modulating NO- system may be practically translated into an enhanced clinical performance remains to be determined. Expand
Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.
Supporting evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis. Expand
Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats.
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 inhibited the pathology seen with ibuprofen, including hepatic encephalopathy, the gastric lesions, hepatomegaly, and increased liver serum values. Expand
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.
The very extensive antagonization of diclofenac toxicity achieved with BPC 157 (μg-/ng-regimen, intraperitoneally, per-orally) may encourage its further use as a therapy to counteract dicL ofenac- and other NSAID-induced toxicity. Expand
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
In rat esophagitis and failed function of both lower esophageal sphincter (LES) and pyloricSphincters (PS), BPC 157 increased pressure in both spHincters till normal and reduced esophAGitis, and may improve gastrointestinal tract therapy. Expand